TNFRSF9 and neoplasm: Additionally, incorporating co‐stimulatory receptor agonists, such as OX40 or 4‐1BB, can further enhance T cell activation and proliferation, effectively counteracting tumour‐induced immune suppression and achieving sustained immune responses.165, 166